Benefits of HIV drugs rise, but less than previously believed

The researchers analyzed 32,483 HIV-infected patients cared for in 12 clinics across the United States between 2001 and 2010. patients in the U.S. During that time, the percentage of patients taking antiretroviral drugs who exhibited sustained viral suppression -- having no detectable HIV virus in the blood every time the virus is measured -- increased from 45 percent to 72 percent. The authors point to new drugs and fixed dose combination tablets as factors in improving the efficacy and safety of antiretroviral drug regimens, as well as decreased side effects that make patients more likely to adhere to their treatment. Better access to care during this time period may also be a contributor to the improved viral suppression rates observed in the study.

Despite this increase, the number of patients with tightly controlled HIV infection was significantly less than the 77 percent to 87 percent figures reported in prior studies, which were based on one-time only measures of HIV virus in the blood, rather than considering every time the virus was measured. According to the study's lead investigator, Baligh Yehia, MD, MSHP, MPP, a fellow in the division of Infectious Diseases at Penn Medicine and HIV specialist, "if the HIV virus is not fully suppressed, individuals are at risk of transmitting HIV to others in the community." Yehia says that while significant advances in HIV therapy have occurred over the past decade, consistent adherence to medicines and outpatient care remains a major hurdle for many people living with HIV. The findings come on the heels of the Food and Drug Administration's approval this month of the first drug to prevent HIV infection. Similar to people living with HIV, healthy individuals without HIV infection who chose to take this preventative medication need to have strict drug adherence and frequent HIV testing in order to achieve benefit.

Overall, sustained viral suppression was lower for black patients and injection drug users, while older patients and those with private insurance were the most likely to have sustained viral suppression. "Our analysis showed that HIV care providers need to closely monitor younger patients, African-Americans, injection drug users, and individuals without health insurance to ensure that they have access to HIV drugs and adhere to therapy, since those patients appeared to be least likely to have their infection in tight control," said the study's senior author Kelly Gebo, MD, MPH, an associate professor of medicine at the Johns Hopkins University.

"There is no denying the progress we have made over the past decade," says Yehia, "but, more resources and new technology are needed to ensure that more patients have access to HIV therapy and obtain the full benefits of these drugs."

Funding for the study came from the Agency for Healthcare Research and Quality (AHRQ) (290-01-0012), and the National Institutes of Health (K24 AI073957, K24 DA 00432, R01DA11602, and R01 AA 16893).